MedTrace Logo

LEV102 Topical Gel in Acquired Blepharoptosis

NCT05715346 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-11-13

Study results available
· View outcomes & findings →

Summary

Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.

Conditions

  • Acquired Blepharoptosis

Interventions

DRUG

LEV102 1.0%

Oxymetazoline ophthalmic gel

DRUG

LEV102 2.0%

Oxymetazoline ophthalmic gel

DRUG

Vehicle

Vehicle ophthalmic gel

Sponsors & Collaborators

  • Levation Pharma, Ltd.

    lead INDUSTRY

Principal Investigators

  • Houman D Hemmati, MD PhD · Levation Pharma, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2023-06-24
Completion
2023-06-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05715346 on ClinicalTrials.gov